Search Results - "Hall, Gerald" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

by Schaer, David A, Geeganage, Sandaruwan, Amaladas, Nelusha, Lu, Zhao Hai, Rasmussen, Erik R, Sonyi, Andreas, Chin, Darin, Capen, Andrew, Li, Yanxia, Meyer, Catalina M, Jones, Bonita D, Huang, Xiaodong, Luo, Shuang, Carpenito, Carmine, Roth, Kenneth D, Nikolayev, Alexander, Tan, Bo, Brahmachary, Manisha, Chodavarapu, Krishna, Dorsey, Frank C, Manro, Jason R, Doman, Thompson N, Donoho, Gregory P, Surguladze, David, Hall, Gerald E, Kalos, Michael, Novosiadly, Ruslan D
Published in Clinical cancer research (01.12.2019)

Get full text

Journal Article

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

by Holmgaard, Rikke B, Schaer, David A, Li, Yanxia, Castaneda, Stephen P, Murphy, Mary Y, Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R, Iversen, Philip W, Surguladze, David, Hall, Gerald E, Novosiadly, Ruslan D, Benhadji, Karim A, Plowman, Gregory D, Kalos, Michael, Driscoll, Kyla E
Published in Journal for immunotherapy of cancer (04.06.2018)

Get full text

Journal Article

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

by Li, Yanxia, Amaladas, Nelusha, O'Mahony, Marguerita, Manro, Jason R, Inigo, Ivan, Li, Qi, Rasmussen, Erik R, Brahmachary, Manisha, Doman, Thompson N, Hall, Gerald, Kalos, Michael, Novosiadly, Ruslan, Puig, Oscar, Pytowski, Bronislaw, Schaer, David A
Published in PloS one (18.07.2022)

Get full text

Journal Article

Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma

Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma

by Chaudhary, Ritu, Slebos, Robbert J. C., Song, Feifei, McCleary‐Sharpe, Keegan P., Masannat, Jude, Tan, Aik Choon, Wang, Xuefeng, Amaladas, Nelusha, Wu, Wenjuan, Hall, Gerald E., Conejo‐Garcia, Jose R., Hernanez‐Prera, Juan C., Chung, Christine H.
Published in Molecular carcinogenesis (01.02.2021)

Get full text

Journal Article

Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor

Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor

by Sato, Takamichi, Forest, Amelie, Kandaswamy, Veena, Hall, Gerald, Yamada, Masatoshi
Published in Gan to kagaku ryoho (01.12.2023)

Get more information

Journal Article

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

by Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N, Ludwig, Dale L, Novosiadly, Ruslan D, Kalos, Michael
Published in Journal for immunotherapy of cancer (30.04.2018)

Get full text

Journal Article

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

by Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N, Ludwig, Dale L, Novosiadly, Ruslan D, Kalos, Michael
Published in Journal for immunotherapy of cancer (04.06.2018)

Get full text

Journal Article

Characterization of Randomly-Obtained Matrix Attachment Regions (MARs) from Higher Plants

Characterization of Randomly-Obtained Matrix Attachment Regions (MARs) from Higher Plants

by Michalowski, Susan M, Allen, George C, Hall, Gerald E, Thompson, William F, Spiker, Steven
Published in Biochemistry (Easton) (28.09.1999)

Get full text

Journal Article

Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC)

Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC)

by Chaudhary, Ritu, Slebos, Robbert, Song, Feifei, McCleary-Sharpe, Keegan, Masannat, Jude, Tan, Aik Choon, Wang, Xuefeng, Amaladas, Nelusha, Wu, Wenjuan, Hall, Gerald, Chung, Christine H.
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

Cover Image, Volume 60, Issue 2

Cover Image, Volume 60, Issue 2

by Chaudhary, Ritu, Slebos, Robbert J. C., Song, Feifei, McCleary‐Sharpe, Keegan P., Masannat, Jude, Tan, Aik Choon, Wang, Xuefeng, Amaladas, Nelusha, Wu, Wenjuan, Hall, Gerald E., Conejo‐Garcia, Jose R., Hernanez‐Prera, Juan C., Chung, Christine H.
Published in Molecular carcinogenesis (01.02.2021)

Get full text

Journal Article

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

by Kandaswamy, Veena, Forest, Amelie, Deroose, Marianne, Schaer, David A., Chen, Ting, Liu, Shengwu, Surguladze, David, Yao, Yung-mae, Doman, Thompson, Hall, Gerald, Wong, Kwok-Kin, Kalos, Michael, Novosiadly, Ruslan D.
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

by Novosiadly, Ruslan, Schaer, David, Amaladas, Nelusha, Rasmussen, Erik, Lu, Zhao Hai, Sonyi, Andreas, Carpenito, Carmine, Li, Yanxia, Luo, Shuang, Capen, Andrew, Meyer, Catalina, Huang, Xiaodong, Manro, Jason, Donoho, Gregory, Doman, Thompson, Hall, Gerald, Geeganage, Sandaruwan, Kalos, Michael
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

by Schaer, David A., Amaladas, Nelusha, Lu, Zhao Hai, Rasmussen, Erik, Sonyi, Andreas, Chin, Darin, Capen, Andrew, Li, Yanxia, Meyer, Catalina, Jones, Bonita, Hong, Xiaodong, Luo, Shuang, Carpenito, Carmine, Roth, Kenneth, Nikolayev, Alexander, Tan, Bo, Brahmachary, Manisha, Chodavarapu, Krishna, Dorsey, Frank Charles, Manro, Jason, Doman, Thompson, Donoho, Greg, Surguladze, David, Hall, Gerald, Geeganage, Sandaruwan, Kalos, Michael, Novosiadly, Ruslan
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

by Forest, Amelie, Rasmussen, Erik R., Doman, Thompson N., Amatulli, Michael, Bassi, Rajiv, Hall, Gerald E., Manro, Jason R., Brahmachary, Manisha, Surguladze, David, Yao, Yung-mae M., Kalos, Michael D., Novosiadly, Ruslan D.
Published in Molecular cancer therapeutics (01.01.2018)

Get full text

Journal Article

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

by Melchior, Maxine A., Guo, Xuemei, Donoho, Gregory P., Iversen, Philip W., Doman, Thompson N., Brahmachary, Manisha, Gong, Xueqian, Hall, Gerald E., Manro, Jason R., Yao, Yung-mae M., Buchanan, Sean, Smeal, Tod, Kalos, Michael D., Novosiadly, Ruslan D.
Published in Molecular cancer therapeutics (01.01.2018)

Get full text

Journal Article

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

by Carpenito, Carmine, Li, Yiwen, Wang, George X., Malabunga, Maria S., Haidar, Jaafar N., Forest, Amelie, Murphy, Mary Y., Hall, Gerald E., Wang, Cindy, Shen, Leyi, Sonyi, Andreas, Chin, Darin, Pennello, Anthony L., Inigo, Ivan V., Surguladze, David, Yao, Yung-mae, Burtrum, Douglas, Novosiadly, Ruslan D., Persaud, Kris, Ludwig, Dale L., Kalos, Michael D.
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

by Yan, Sau-Chi Betty, Peek, Victoria L., Stephens, Jennifer R., Um, Um L., Nelusha, Amaladas, Burns, Colleen A., Credille, Kelly M., Doman, Thompson N., Eastman, Scott W., Falcon, Beverly L., Hall, Gerald E., Iversen, Philip W., Konicek, Bruce W., Manro, Jason R., Pappas, Any T., Stewart, Julie A., Topper, Michael B., Wong, Swee-Seong, Kalos, Michael, Novosiadly, Ruslan D., Walgren, Richard A., Schaer, David
Published in Cancer research (Chicago, Ill.) (01.07.2017)

Get full text

Journal Article

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

by Holmgaard, Rikke B, Schaer, David A, Li, Yanxia, Castaneda, Stephen P, Murphy, Mary Y, Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R, Iversen, Philip W, Surguladze, David, Hall, Gerald E, Novosiadly, Ruslan D, Benhadji, Karim A, Plowman, Gregory D, Kalos, Michael, Driscoll, Kyla E
Published in Journal for immunotherapy of cancer (04.06.2018)

Get full text

Journal Article

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

by Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Published in Journal for immunotherapy of cancer (04.11.2015)

Get full text

Journal Article

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

by Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Published in Journal for immunotherapy of cancer (04.11.2015)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[20]